Literature DB >> 26217391

Treatment of Polyostotic Fibrous Dysplasia of the Thoracic Spine with Intravenous Pamidronate: Result from 9 Months Follow Up.

Jongjoo Lee1, Hyunchul Shin1, Young-Jun Kwon1.   

Abstract

Fibrous dysplasia of the spine is very rarely observed. We reported a case of a 57-year-old woman, who presented with neck and bilateral shoulder pain with histologically confirmed fibrous dysplasia, involving the first and second thoracic vertebrae. Clinical and radiological findings were not specific for fibrous dysplasia. The histological biopsy was required for a confirmed diagnosis. Endocrine and metabolic evaluations are required to rule out diseases such as hyperthyroidism, Cushing syndrome and osteomalacia. Fibrous dyplasia can be managed by appropriate medical and surgical treatments based on the patient's neurological status and symptoms. Our patient was given intravenous pamidronate 60mg/day for 3 days. After 9 months, her initial symptoms were improved, but computed tomography scan of the thoracic spine showed no change of the lesions.

Entities:  

Keywords:  Fibrous dysplasia of bone; Pamidronate; Thoracic spine

Year:  2015        PMID: 26217391      PMCID: PMC4513177          DOI: 10.14245/kjs.2015.12.2.95

Source DB:  PubMed          Journal:  Korean J Spine        ISSN: 1738-2262


  18 in total

Review 1.  Monostotic fibrous dysplasia of the thoracic spine. A case report.

Authors:  G J Przybylski; I F Pollack; W T Ward
Journal:  Spine (Phila Pa 1976)       Date:  1996-04-01       Impact factor: 3.468

Review 2.  Symptomatic monostotic fibrous dysplasia of the thoracic spine.

Authors:  M Oba; W Nakagami; M Maeda; K Kobayashi
Journal:  Spine (Phila Pa 1976)       Date:  1998-03-15       Impact factor: 3.468

Review 3.  Fibrous dysplasia of the spine with sarcomatous transformation: a case report and review of the literature.

Authors:  E Yalniz; T Er; F Ozyilmaz
Journal:  Eur Spine J       Date:  1995       Impact factor: 3.134

4.  Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.

Authors:  R D Chapurlat; P Hugueny; P D Delmas; P J Meunier
Journal:  Bone       Date:  2004-07       Impact factor: 4.398

5.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.

Authors:  L S Weinstein; A Shenker; P V Gejman; M J Merino; E Friedman; A M Spiegel
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

6.  Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis.

Authors:  Arabella I Leet; Edward Magur; Janice S Lee; Shlomo Wientroub; Pamela G Robey; Michael T Collins
Journal:  J Bone Joint Surg Am       Date:  2004-03       Impact factor: 5.284

7.  Fibrous dysplasia of the first cervical vertebra.

Authors:  Mavilde Arantes; Artur Rocha Vaz; Mrinalini Honavar; Mário Resende; Jorge Resende Pereira
Journal:  Spine (Phila Pa 1976)       Date:  2008-11-15       Impact factor: 3.468

8.  Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia.

Authors:  G A Candeliere; F H Glorieux; J Prud'homme; R St-Arnaud
Journal:  N Engl J Med       Date:  1995-06-08       Impact factor: 91.245

9.  Odontoid fracture complicating Jaffe-Lichtenstein disease. Case report.

Authors:  Johann Peltier; Michel Lefranc; Anthony Fichten; Carole Cordonnier; Patrick Toussaint; Christine Desenclos; Daniel Le Gars
Journal:  J Neurosurg Spine       Date:  2008-03

Review 10.  Fibrous dysplasia of the mobile spine: report of 8 cases and review of the literature.

Authors:  Feng Liang Wu; Liang Jiang; Chen Liu; Shao Min Yang; Feng Wei; Lei Dang; Xiao Guang Liu; Zhong Jun Liu
Journal:  Spine (Phila Pa 1976)       Date:  2013-11-01       Impact factor: 3.468

View more
  1 in total

Review 1.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.